Allosteric drug developer Nutshell Therapeutics announced on Monday that it has closed $40 million in a Series A+ round of financing. Separately, Shanghai UniXell Biotechnology has raised nearly 200 million yuan ($31.5 million) in a Pre-A round of financing.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
